Survivorship and quality of life in head and neck cancer

Journal of Clinical Oncology

Volumn 33, Issue 29, 2015, Pages 3322-3327

  Ringash, Jolie ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SURVIVAL; CANCER SURVIVOR; CLINICAL RESEARCH; FUNCTIONAL ASSESSMENT; HEAD AND NECK CANCER; HEALTH STATUS; HUMAN; KARNOFSKY PERFORMANCE STATUS; OUTCOME ASSESSMENT; PERSONAL EXPERIENCE; PERSONALITY; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; REVIEW; HEAD AND NECK TUMOR; HEALTH SERVICE; PATHOPHYSIOLOGY; PROGNOSIS; PSYCHOLOGY; SQUAMOUS CELL CARCINOMA; SURVIVOR;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; PROGNOSIS; QUALITY OF LIFE; SURVIVORS;

EID: 84944250542     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.4115     Document Type: Review

References (68)

1. Pulte D, Brenner H: Changes in survival in head and neck cancers in the late 20th and early 21st century: A period analysis. Oncologist 15: 994-1001, 2010
2. Franceschi S, Muñoz N, Bosch XF, et al: Human papillomavirus and cancers of the upper aerodigestive tract: A review of epidemiological and experimental evidence. Cancer Epidemiol Biomarkers Prev 5: 567-575, 1996
3. Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363: 24-35, 2010
4. Chaturvedi AK, Engels EA, Anderson WF, et al: Incidence trends for human papillomavirusrelated and unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26: 612-619, 2008
5. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al: Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 31: 4550-4559, 2013
6. Frisch M, Hjalgrim H, Jaeger AB, et al: Changing patterns of tonsillar squamous cell carcinoma in the United States. Cancer Causes Control 11: 489-495, 2000
7. Mariotto AB, Yabroff KR, Shao Y, et al: Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103: 117-128, 2011
8. Hewitt M, Greenfield S, Stovall E (eds): From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC, National Academies Press, 2005
9. Bell K, Ristovski-Slijepcevic S: Cancer survivorship: Why labels matter. J Clin Oncol 31: 409-411, 2013
10. National Coalition for Cancer Survivorship: Defining cancer survivorship. http: //www.canceradvocacy.org/ news/defining-cancer-survivorship/
11. McDowell ME, Occhipinti S, Ferguson M, et al: Predictors of change in unmet supportive care needs in cancer. Psycho-oncology 19: 508-516, 2009
12. Henry M, Habib L-A, Morrison M, et al: Head and neck cancer patients want us to support them psychologically in the posttreatment period: Survey results. Palliat Support Care 24: 1-13, 2013
13. Trotti A, Pajak TF, Gwede CK, et al: TAME: Development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol 8: 613-624, 2007
14. Martino R, Ringash J: Evaluation of quality of life and organ function in head and neck squamous cell carcinoma. Hematol Oncol Clin North Am 22: 1239-1256, 2008
15. Ringash J, Bernstein LJ, Cella D, et al: Outcomes toolbox for head and neck cancer research. Head Neck 37: 425-439, 2015
16. Karnofsky DA, Abelmann WH, Craver LF, et al: The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1: 634-656, 1948
17. Rehabilitation after cardiovascular diseases, with special emphasis on developing countries: Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 831: 1-122, 1993
18. Political Behavior Program, the Survey Research Center of the Institute of Social Research, University of Michigan: National Election Studies, 1964: Pre/Post Election Study. Ann Arbor, MI, University of Michigan, Center for Political Studies, 1999
19. US Department of Health and Human Services: Guidance for industry: Patient-reported outcome measures-Use in medical product development to support labeling claims. http: //www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM193282.pdf
20. Schoemaker PJH: The expected utility model: Its variants, purposes and limitations. J Econ Lit 20: 529-563, 1982
21. Feinstein AR: Clinimetrics. New Haven, CT, Yale University Press, 1987
22. US Department of Health and Human Services: Common Terminology Criteria for Adverse Events, version 4.0. http: //evs.nci.nih.gov/ftp1/CTCAE/ CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf
23. Woodard CA, Chambers LW: Guide to Questionnaire Construction and Question Writing. Ottawa, Ontario, Canada, Canadian Public Health Association, 1980
24. Cull A, Sprangers M, Bjordal K, et al: EORTC Quality of Life Group Translation Procedure. Brussels, Belgium, European Organisation for Research and Treatment of Cancer, 2002
25. Reeve B, Hays R, Bjorner J, et al: Psychometric evaluation and calibration of health-related quality of life item banks: Plans for the Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care 45: S22-S31, 2007 (suppl 1)
26. Wright JG: The minimal important difference: Who's to say what is important? J Clin Epidemiol 49: 1221-1222, 1996
27. Ringash J, O'Sullivan B, Bezjak A, et al: Interpreting clinically significant changes in patientreported outcomes. Cancer 110: 196-202, 2007
28. Norman GR, Sloan JA, Wyrwich KW: Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care 41: 582-592, 2003
29. Sprangers MA, Schwartz CE: Integrating response shift into health-related quality of life research: A theoretical model. Soc Sci Med 48: 1507-1515, 1999
30. Holzner B, Kemmler G, Cella D, et al: Normative data for Functional Assessment of Cancer Therapy- General Scale and its use for the interpretation of quality of life scores in cancer survivors. Acta Oncol 43: 153-160, 2004
31. Guren MG, Dueland S, Skovlund E, et al: Quality of life during radiotherapy for rectal cancer. Eur J Cancer 39: 587-594, 2003
32. Osoba D, Zee B: Completion rates in healthrelated quality-of-life assessment: Approach of the National Cancer Institute of Canada Clinical Trials Group. Stat Med 17: 603-612, 1998
33. Davis D, Evans M, Jadad A, et al: The case for knowledge translation: Shortening the journey from evidence to effect. BMJ 327: 33-35, 2003
34. Bezjak A, Ng P, Skeel R, et al: Oncologists' use of quality of life information: Results of a survey of Eastern Cooperative Oncology Group physicians. Qual Life Res 10: 1-13, 2001
35. Rouette J, Blazeby J, King M, et al: Integrating health-related quality of life findings from randomized clinical trials into oncology practice: An international study of oncologists' perspectives. Qual Life Res 24: 1317-1325, 2015
36. Laupacis A, Sackett DL, Roberts RS: An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318: 1728-1733, 1988
37. Osoba D, Bezjak A, Brundage M, et al: Analysis and interpretation of health-related quality-oflife data from clinical trials: Basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 41: 280-287, 2005
38. Guyatt GH, Naylor CD, Juniper E, et al: Users' guides to the medical literature: XII. How to use articles about health-related quality of life- Evidence-Based Medicine Working Group. JAMA 277: 1232-1237, 1997
39. Sprangers MA, Moinpour CM, Moynihan TJ, et al: Assessing meaningful change in quality of life over time: A users' guide for clinicians. Mayo Clin Proc 77: 561-571, 2002
40. Brundage M, Blazeby J, Revicki D, et al: Patient-reported outcomes in randomized clinical trials: Development of ISOQOL reporting standards. Qual Life Res 22: 1161-1175, 2013
41. Brundage M, Bass B, Davidson J, et al: Patterns of reporting health-related quality of life outcomes in randomized clinical trials: Implications for clinicians and quality of life researchers. Qual Life Res 20: 653-664, 2011
42. Klein J, Livergant J, Ringash J: Health related quality of life in head and neck cancer treated with radiation therapy with or without chemotherapy: A systematic review. Oral Oncol 50: 254-262, 2014
43. Curran D, Giralt J, Harari PM, et al: Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 25: 2191-2197, 2007
44. Pow EH, Kwong DL, McMillan AS, et al: Xerostomia and quality of life after intensitymodulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 66: 981-991, 2006
45. Rathod S, Gupta T, Ghosh-Laskar S, et al: Quality of life (QOL) outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with intensity-modulated radiation therapy (IMRT) compared to three-dimensional conformal radiotherapy (3D-CRT): Evidence from a prospective randomized study. Oral Oncol 49: 634-642, 2013
46. Bottomley A, Tridello G, Coens C, et al: An international phase 3 trial in head and neck cancer: Quality of life and symptom results-EORTC 24954 on behalf of the EORTC Head and Neck and the EORTC Radiation Oncology Group. Cancer 120: 390-398, 2014
47. Ackerstaff AH, Rasch CR, Balm AJ, et al: Five-year quality of life results of the randomized clinical phase III (RADPLAT) trial, comparing concomitant intra-arterial versus intravenous chemoradiotherapy in locally advanced head and neck cancer. Head Neck 34: 974-980, 2012
48. van Herpen CM, Mauer ME, Mesia R, et al: Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil (TPF) and cisplatin, 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX323). Br J Cancer 103: 1173-1181, 2010
49. van der Meulen IC, May AM, de Leeuw JR, et al: Long-term effect of a nurse-led psychosocial intervention on health-related quality of life in patients with head and neck cancer: A randomized controlled trial. Br J Cancer 110: 593-601, 2014
50. Antunes HS, Herchenhorn D, Small IA, et al: Phase III trial of low-level laser therapy to prevent oral mucositis in head and neck cancer patients treated with concurrent chemoradiation. Radiother Oncol 109: 297-302, 2013
51. Gautam AP, Fernandes DJ, Vidyasagar MS, et al: Effect of low-level laser therapy on patient reported measures of oral mucositis and quality of life in head and neck patients receiving chemoradiotherapy: A randomized controlled trial. Support Care Cancer 21: 1421-1428, 2013
52. Oton-Leite AF, Corrêade Castro AC, Morais MO, et al: Effect of intraoral low-level laser therapy on quality of life of patients with head and neck cancer undergoing radiotherapy. Head Neck 34: 398-404, 2012
53. Silander E, Nyman J, Bove M, et al: Impact of prophylactic percutaneous endoscopic gastrostomy on malnutrition and quality of life in patients with head and neck cancer: A randomized study. Head Neck 34: 1-9, 2012
54. Ringash J, Warde P, Lockwood G, et al: Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia. Int J Radiat Oncol Biol Phys 61: 1403-1407, 2005
55. Fisher J, Scott C, Scarantino CW, et al: Phase III quality-of-life study results: Impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer-RTOG 97-09. Int J Radiat Oncol Biol Phys 56: 832-836, 2003
56. Duncan GG, Epstein JB, Tu D, et al: Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: A report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head Neck 27: 421-428, 2005
57. Elliott EA, Wright JR, Swann RS, et al: Phase III trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: Results of Radiation Therapy Oncology Group Trial 99-13. J Clin Oncol 24: 2092-2097, 2006
58. Hoffman KE, Pugh SL, James JL, et al: The impact of concurrent granulocyte-macrophage colony-stimulating factor on quality of life in head and neck cancer patients: Results of the randomized, placebo-controlled Radiation Therapy Oncology Group 9901 trial. Qual Life Res 23: 1841-1858, 2014
59. Rogers LQ, Anton PM, Fogleman A, et al: Pilot, randomized trial of resistance exercise during radiation therapy for head and neck cancer. Head Neck 35: 1178-1188, 2013
60. Samuel SR, Maiya GA, Babu AS, et al: Effect of exercise training on functional capacity & quality of life in head & neck cancer patients receiving chemoradiotherapy. Indian J Med Res 137: 515-520, 2013
61. Lønbro S, Dalgas U, Primdahl H, et al: Progressive resistance training rebuilds lean body mass in head and neck cancer patients after radiotherapy: Results from the randomized DAHANCA 25B trial. Radiother Oncol 108: 314-319, 2013
62. Goldstein DP, Hynds Karnell L, Christensen AJ, et al: Health-related quality of life profiles based on survivorship status for head and neck cancer patients. Head Neck 29: 221-229, 2007
63. Siddiqui F, Pajak TF, Watkins-Bruner D, et al: Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: A Radiation Therapy Oncology Group analysis. Int J Radiat Oncol Biol Phys 70: 353-360, 2008
64. Guyatt GH, Ferrans CE, Halyard MY, et al: Exploration of the value of health-related quality-of-life information from clinical research and into clinical practice. Mayo Clin Proc 82: 1229-1239, 2007
65. Ringash J, Macedo A, Li M, et al: Routine clinical quality of life measurement for head and neck cancer patients: Example from a province-wide oncology initiative. Qual Life Res 23: 55-56, 2014 (suppl; abstr 210.6)
66. National Comprehensive Cancer Center: NCCN guidelines for head and neck cancer. http: // www.nccn.org/professionals/physician-gls/pdf/headand- neck.pdf
67. Baxi SS, Pinheiro LC, Patil SM, et al: Causes of death in long-term survivors of head and neck cancer. Cancer 120: 1507-1513, 2014
68. Ringash J: Facing head and neck cancer deaths head on: Lessons for survival. Cancer 120: 1446-1449, 2014